Mar 26, 2026 8:30am EDT RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
Mar 23, 2026 8:30am EDT RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Mar 20, 2026 8:30am EDT RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
Feb 27, 2026 8:30am EST RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
Feb 26, 2026 8:30am EST RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
Feb 05, 2026 8:30am EST RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Feb 04, 2026 8:30am EST RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
Jan 28, 2026 8:30am EST RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
